Cargando…

Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

BACKGROUND: The added value of radiotherapy following neoadjuvant FOLFIRINOX chemotherapy in patients with resectable or borderline resectable pancreatic cancer ((B)RPC) is unclear. The objective of this meta-analysis was to compare outcomes of patients who received neoadjuvant FOLFIRINOX alone or c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janssen, Quisette P., van Dam, Jacob L., Kivits, Isabelle G., Besselink, Marc G., van Eijck, Casper H. J., Homs, Marjolein Y. V., Nuyttens, Joost J. M. E., Qi, Hongchao, van Santvoort, Hjalmar J., Wei, Alice C., de Wilde, Roeland F., Wilmink, Johanna W., van Tienhoven, Geertjan, Groot Koerkamp, Bas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Pancreatic Tumors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591030/ https://www.ncbi.nlm.nih.gov/pubmed/34142290 http://dx.doi.org/10.1245/s10434-021-10276-8

Ejemplares similares

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study
por: van Veldhuisen, Eran, et al.
Publicado: (2022)

Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival in Pancreatoduodenectomy for Pancreatic Cancer
por: Augustinus, Simone, et al.
Publicado: (2023)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria
por: Anger, Friedrich, et al.
Publicado: (2020)

FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
por: Eshmuminov, Dilmurodjon, et al.
Publicado: (2023)

Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis
por: Henry, Anne Claire, et al.
Publicado: (2022)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
por: Janssen, Q. P., et al.
Publicado: (2021)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer
por: Schouten, Thijs J., et al.
Publicado: (2022)

How to Approach Para-Aortic Lymph Node Metastases During Exploration for Suspected Periampullary Carcinoma: Resection or Bypass?
por: Pranger, Bobby K., et al.
Publicado: (2020)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer
por: Rombouts, Steffi J., et al.
Publicado: (2016)

Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials
por: Doppenberg, Deesje, et al.
Publicado: (2023)

Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study
por: van der Sijde, Fleur, et al.
Publicado: (2022)

CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Maggino, Laura, et al.
Publicado: (2022)

Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study
por: Lof, Sanne, et al.
Publicado: (2019)

Surgical Outcome After Pancreatoduodenectomy for Duodenal Adenocarcinoma Compared with Other Periampullary Cancers: A Nationwide Audit Study
por: de Bakker, Jacob K., et al.
Publicado: (2022)

Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis
por: de Rooij, Thijs, et al.
Publicado: (2015)

Treatment and Survival of Elderly Patients with Stage I–II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium
por: Groen, Jesse V., et al.
Publicado: (2020)

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
por: van Dam, J. L., et al.
Publicado: (2023)

Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study
por: Chen, Jeffrey W., et al.
Publicado: (2023)

Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients
por: van der Sijde, Fleur, et al.
Publicado: (2022)

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
por: Suker, Mustafa, et al.
Publicado: (2018)

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)

What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?
por: Navez, Julie, et al.
Publicado: (2021)

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX
por: van der Sijde, Fleur, et al.
Publicado: (2021)

Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis
por: Tanaka, Masayuki, et al.
Publicado: (2022)

Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer
por: Holyoake, Daniel L.P., et al.
Publicado: (2016)

Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study
por: Klompmaker, Sjors, et al.
Publicado: (2018)

Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67
por: Genç, C. G., et al.
Publicado: (2018)

A Case of Gastric Heterotopic Pancreatitis Resected by Laparoscopic Surgery
por: Matsumoto, Takatsugu, et al.
Publicado: (2015)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Prognostic Impact of Resection Margin Status in Distal Pancreatectomy for Ductal Adenocarcinoma
por: Sahakyan, Mushegh A., et al.
Publicado: (2021)

Skeletal Muscle Quality is Associated with Worse Survival After Pancreatoduodenectomy for Periampullary, Nonpancreatic Cancer
por: Van Rijssen, L. B., et al.
Publicado: (2016)

Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma
por: Malleo, Giuseppe, et al.
Publicado: (2021)

The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study
por: Leonhardt, Carl-Stephan, et al.
Publicado: (2022)

Is Laparoscopic Liver Resection Safe and Comparable to Open Liver Resection for Hepatocellular Carcinoma?
por: Nguyen, Kevin Tri, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_mbppk4g5ibk9ada02k382799ph